beta-caryophyllene
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2020 (NCT04451863)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cannabinoid CB1 receptorAGONIST
CNR1 agonist
Chemistry & pharmacology
Loading structure…
SMILES
C=C1CC/C=C(\C)CC[C@@H]2[C@@H]1CC2(C)C- Mol. weight
- 204.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL445740 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04794205 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2021 | University of Connecticut, Yale University |
| NCT04451863 | Phase 1 | Nov 30, 2020 | National Center for Complementary and Integrative Health (NCCIH), University of California, Los Angeles |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Center for Complementary and Integrative Health (NCCIH) | Government | 1 | 0 | 1 | 2020 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Connecticut | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1